62,734
edits
Changes
no edit summary
| 2016 || || || Commercial launch || A partially effective {{w|dengue vaccine}} (Dengvaxia) becomes commercially available in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Thailand, and Singapore.<ref name="reuters.com">{{cite web|title=Sanofi's dengue vaccine approved in 11 countries|url=https://www.reuters.com/article/us-sanofi-vacccine-idUSKCN1240C5|website=Reuters|accessdate=25 April 2018}}</ref><ref>{{cite news|last1=East|first1=Susie|title=World's first dengue fever vaccine launched in the Philippines|url=http://edition.cnn.com/2016/04/06/health/dengue-fever-vaccine-philippines/|accessdate=25 April 2018|publisher=CNN}}</ref> ||
|-
| 2016 || || {{w|DiphteriaDiphtheria}} || Statistics || About 86% of the world population was vaccinated as of year.<ref name="auto">{{cite web|title=Diphtheria|url=http://www.who.int/immunization/monitoring_surveillance/burden/diphtheria/en/|website=[[World Health Organization]] (WHO)|accessdate=1 June 2020|date=3 September 2014|url-status=live}}</ref> || Worldwide
|-
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2019 || December 3 || {{w|Anthrax}} || Recommendation || "CDC published ACIP recommendations on the use of BioThrax (anthrax vaccine, adsorbed; Emergent BioSolutions)" <ref>{{cite web |title=Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019 |url=https://www.cdc.gov/mmwr/volumes/68/rr/pdfs/rr6804a1-H.pdf |website=cdc.gov |accessdate=1 June 2020}}</ref>||
|-
| 2019 || December 19 || {{w|Ebola}} || Vaccine approval || "First FDA-approved vaccine for the prevention of Ebola virus"<ref>{{cite web |title=First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response |url=https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health |website=fda.gov |accessdate=1 June 2020}}</ref> || {{w|United States}}
|-
| 2020 || January 24 || {{w|Diphtheria}}, {{w|tetanus}}, {{w|pertussis}} || Recommendation || "CDC published updated ACIP DTaP Vaccine Recommendations, CDCrecommendations on the use of Td and Tdap vaccines."<ref>{{cite web |title=DTaP/Tdap/Td ACIP Vaccine Recommendations |url=https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dtap.html |website=cdc.gov |accessdate=1 June 2020}}</ref> || {{w|United States}}
|-
| 2020 || January 30 || || Background || [[CDC]] declares public health emergency regarding 2019 novel coronavirus. || {{w|United States}}
